Ritholtz Wealth Management Has $552,000 Holdings in argenx SE (NASDAQ:ARGX)

Ritholtz Wealth Management increased its holdings in shares of argenx SE (NASDAQ:ARGX) by 85.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 898 shares of the company’s stock after purchasing an additional 414 shares during the quarter. Ritholtz Wealth Management’s holdings in argenx were worth $552,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Cromwell Holdings LLC boosted its stake in shares of argenx by 73.3% during the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after buying an additional 66 shares during the last quarter. GAMMA Investing LLC raised its holdings in argenx by 47.5% during the third quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock worth $94,000 after acquiring an additional 56 shares in the last quarter. Point72 Hong Kong Ltd acquired a new position in argenx during the second quarter valued at approximately $76,000. Fulton Bank N.A. bought a new position in argenx in the fourth quarter valued at approximately $226,000. Finally, Blue Trust Inc. increased its position in shares of argenx by 413.9% during the 3rd quarter. Blue Trust Inc. now owns 370 shares of the company’s stock worth $201,000 after purchasing an additional 298 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ARGX has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft downgraded argenx from a “hold” rating to a “sell” rating in a report on Friday. Oppenheimer reissued an “outperform” rating and issued a $675.00 price objective (up previously from $646.00) on shares of argenx in a research report on Thursday, November 21st. Wolfe Research raised shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 target price on the stock in a report on Tuesday, November 12th. Robert W. Baird downgraded shares of argenx from an “outperform” rating to a “neutral” rating and raised their target price for the company from $515.00 to $650.00 in a research note on Friday, November 1st. Finally, HC Wainwright reissued a “buy” rating and set a $717.00 price target (up previously from $670.00) on shares of argenx in a research report on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $658.39.

argenx Stock Down 2.9 %

Shares of NASDAQ:ARGX opened at $640.52 on Tuesday. argenx SE has a 12-month low of $349.86 and a 12-month high of $678.21. The company’s 50 day moving average price is $621.22 and its two-hundred day moving average price is $558.80. The firm has a market cap of $38.67 billion, a PE ratio of -727.86 and a beta of 0.59.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. The firm had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same quarter last year, the company earned ($1.25) EPS. On average, research analysts expect that argenx SE will post 2.17 EPS for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.